ArticlePLoS neglected tropical diseases2015
Cloning and Characterization of Two Potent Kunitz Type Protease Inhibitors from Echinococcus granulosus.
Article in PLoS neglected tropical diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.
- Promising effects of parasite-derived compounds on tumor regression: a systematic review of in vitro and in vivo studies.Environmental science and pollution research international · 2022Pooled it
- Heterologous expression and functional characterization of recombinant arenin to assess its anticancer and wound-healing potential.Bioresources and bioprocessing · 2025Article
- Bridging the gap for diverse applications of parasites as advanced cancer therapeutics: current progress and future directions.Infectious agents and cancer · 2025Review
- Echinococcus granulosus sensu lato control measures: a specific focus on vaccines for both definitive and intermediate hosts.Parasites & vectors · 2024Review
- The role of helminths and their antigens in cancer therapy: insights from cell line models.Infectious agents and cancer · 2024Review
- Parasites revive hope for cancer therapy.European journal of medical research · 2024Review
- Parasite-enhanced immunotherapy: transforming the "cold" tumors to "hot" battlefields.Cell communication and signaling : CCS · 2024Review
- Helminth-derived molecules: Pathogenic and pharmacopeial roles.Journal of biomedical research · 2024Article
- Identification and prioritisation of potential vaccine candidates using subtractive proteomics and designing of a multi-epitope vaccine against Wuchereria bancrofti.Scientific reports · 2024Article
- Review
- A candidate virulence factor of Eimeria tenella (EtROP30) predicted by virulence enhancement of transgenic Toxoplasma gondii.Parasitology research · 2023Article
- Parasites as potential targets for cancer immunotherapy.Journal of cancer research and clinical oncology · 2023Review
- Global profiling of the proteome, phosphoproteome, and N-glycoproteome of protoscoleces and adult worms ofFrontiers in veterinary science · 2023Article
- How to train your myeloid cells: a way forward for helminth vaccines?Frontiers in immunology · 2023Review
- Article
- An atypical and functionally diverse family of Kunitz-type cysteine/serine proteinase inhibitors secreted by the helminth parasite Fasciola hepatica.Scientific reports · 2020Article
- Gene expression in human liver fibrosis associated with Echinococcus granulosus sensu lato.Parasitology research · 2020Article
- Kunitz type protease inhibitor from the canine tapeworm as a potential therapeutic for melanoma.Scientific reports · 2019Article
- Echinococcosis: Advances in the 21st Century.Clinical microbiology reviews · 2019Review
- Employing Parasite Against Cancer: A Lesson From the Canine TapewormFrontiers in pharmacology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The tapeworm Echinococcus granulosus is responsible for cystic echinococcosis (CE), a cosmopolitan disease which imposes a significant burden on the health and economy of affected communities. Little is known about the molecular mechanisms whereby E. granulosus is able to survive in the hostile mammalian host environment, avoiding attack by host enzymes and evading immune responses, but protease inhibitors released by the parasite are likely implicated. We identified two nucleotide sequences corresponding to secreted single domain Kunitz type protease inhibitors (EgKIs) in the E. granulosus genome, and their cDNAs were cloned, bacterially expressed and purified. EgKI-1 is highly expressed in the oncosphere (egg) stage and is a potent chymotrypsin and neutrophil elastase inhibitor that binds calcium and reduced neutrophil infiltration in a local inflammation model. EgKI-2 is highly expressed in adult worms and is a potent inhibitor of trypsin. As powerful inhibitors of mammalian intestinal proteases, the EgKIs may play a pivotal protective role in preventing proteolytic enzyme attack thereby ensuring survival of E. granulosus within its mammalian hosts. EgKI-1 may also be involved in the oncosphere in host immune evasion by inhibiting neutrophil elastase and cathepsin G once this stage is exposed to the mammalian blood system. In light of their key roles in protecting E. granulosus from host enzymatic attack, the EgKI proteins represent potential intervention targets to control CE. This is important as new public health measures against CE are required, given the inefficiencies of available drugs and the current difficulties in its treatment and control. In addition, being a small sized highly potent serine protease inhibitor, and an inhibitor of neutrophil chemotaxis, EgKI-1 may have clinical potential as a novel anti-inflammatory therapeutic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.